Pierre Guillou David Jayne REFERENCE: J Clin Oncol 25:3061-3068 PIERRE GUILLOU, St James’ Hospital, Leeds COMMENT: DAVID JAYNE, St James’ Hospital, Leeds Laparoscopic-assisted resection fo

Pierre Guillou

David Jayne
REFERENCE: J Clin Oncol 25:3061-3068
PIERRE GUILLOU, St James’ Hospital, Leeds
COMMENT: DAVID JAYNE, St James’ Hospital, Leeds
Laparoscopic-assisted resection for colorectal cancer has proved just as effective as conventional open surgery, according to researchers in Leeds, England. Peter Goodwin went to meet the chief investigator, Pierre Guillou, to ask him about the CLASSIC study results published in the Journal of Clinical Oncology. David Jayne, also from St James Hospital, told Peter Goodwin about the learning curve associated with laparoscopic-assisted colorectal cancer resection, and reviewed current developments toward fully laparoscopic procedures now being introduced.


Rebecca Silliman
Mammography Surveillance Brings Lower Mortality to Older Breast Cancer Survivors
REFERENCE: J Clin Oncol 25:3001-3006
REBECCA SILLIMAN, Boston Medical Center
A one third reduction in mortality was associated on average with each additional surveillance mammogram among breast cancer survivors older than 65. This emerges from a study published in the Journal of Clinical Oncology by Rebecca Silliman and colleagues in Boston, MA. Peter Goodwin asked her about the clinical messages emerging from these new data.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
Tags
Related Episodes

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer

Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
